Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

Hodgkin lymphoma is a rare B-cell malignant neoplasm affecting approximately 9000 new
patients annually. This disease represents approximately 11% of all lymphomas seen in the …

Background Incorporating brentuximab vedotin into the treatment of advanced-stage classic
Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However …

Background Five-year follow-up in a trial involving patients with previously untreated stage
III or IV classic Hodgkin's lymphoma showed long-term progression-free survival benefits …

Background Brentuximab vedotin is an anti-CD30 antibody–drug conjugate that has been
approved for relapsed and refractory Hodgkin's lymphoma. Methods We conducted an open …

Background We tested interim positron-emission tomography–computed tomography (PET-
CT) as a measure of early response to chemotherapy in order to guide treatment for patients …

Purpose Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-
Sternberg cells within an extensive but ineffective inflammatory/immune cell infiltrate. In cHL …

Background The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated …

PURPOSE Nivolumab, an anti–programmed death-1 monoclonal antibody, has
demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin …

Rationale: Single-center randomized controlled trials of the Zephyr endobronchial valve
(EBV) treatment have demonstrated benefit in severe heterogeneous emphysema. This is …